Biointron x Scientist.com Webinar: Introduction to Bispecific Antibodies and Their Production

Watch the live recording now >>

DATE: Thursday, May 15, 2025

TIME:

• 8:00 am PT (Pacific Time - North America)

• 11:00 am ET (Eastern Time - North America)

• 5:00 pm CET (Central European Time)

In this webinar, Dr. Brady Wu discusses bispecific antibody drugs and their production

First, he will provide a comprehensive overview of the history and development of bispecific antibodies (BsAbs), including their structural biology and strategies like the “common light chain (cLC) approach” to resolve chain mispairing issues. Next, he will elaborate on the mechanisms of action of BsAb drugs and challenges in selecting the most active bispecific candidates: currently, over 100 BsAb structural formats exist, with most designed using “knobs-into-holes (KIH)” engineering principles.

Regarding BsAb production, Dr. Wu will highlight Biointron’s expertise in molecular formats like KIH, IgG-scFv, and IgG-VHH, and present solutions for addressing molecular mispairing and impurity removal during manufacturing. Additionally, he will share case studies and strategies to enhance antibody expression levels and optimize purification processes to meet diverse client requirements.

Finally, Dr. Wu will introduce his company’s infrastructure, R&D advantages in bispecific/multispecific antibody fields, and service features. This will include discussions on platform technologies for accelerating therapeutic development and customized solutions for complex antibody engineering challenges.

Watch the live recording now >>

Key Topics Include:

• Explore the journey of bispecific antibodies from their 1980s origins to cutting-edge products and platforms

• Discuss breakthroughs in the therapeutic area including oncology/immunotherapy

• Analyze the key hurdles in production: structural complexity, stability, and scalable production

Watch the live recording now >>

About the Speaker

Brady Wu, PhD, Head of Protein Center at Biointron

Dr. Brady Wu is a multidisciplinary scientist and biotech leader. He holds a Ph.D. in Chemistry from The Ohio State University (2007–2013), where he pioneered solid-state NMR studies of amyloid fibril dynamics, and a Peking University honors B.S. in Biology (2003–2007). At GenScript (2013–2021), he led 100+ teams in recombinant protein production service and global project management. As the Founding CEO of Solvo Biotherapeutics (2022–2024), he built China’s top cell-free protein synthesis platform with a 15+ team. Now leading the Protein Science group at Biointron (2024–present), he drives ADC conjugation, developability assessment, and recombinant protein/antibody R&D efforts in the company.

Watch the live recording now >>